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Histopathological findings in well functioning, long-term renal al-
lografts. One hundred and twenty-eight patients with a first cadaveric
kidney allograft participated in a prospective, randomized, clinical trial
comparing triple treatment, consisting of initial low-dose cyclosporine
(CsA), azathioprine (Aza) and methylprednisolone (MP), with all pos-
sible combinations of two immunosuppressive drugs. A protocol core
biopsy was performed on all patients with a functioning graft two years
after transplantation. The histological findings were evaluated blindly
and correlated to possible risk factors for renal allograft damage. The
most common histological features were diffuse fibrosis in 62% of
biopsies, tubular atrophy in 64% and diffuse inflammation in 30%. Two
other important findings were glomerulosclerosis (43%) and vascular
intimal proliferation (36%). The histological findings were scored
mostly mild. A total of 77% (69 of 89) of patients had normal or only
slightly increased serum creatinine. Decreased graft function was
related to increased interstitial fibrosis, inflammation, glomerulosclero-
sis, mesangial matrix increase of glomeruli, intimal proliferation of
vessels and tubular atrophy. These findings are characteristic, but not
pathognomonic, of chronic renal allograft rejection both in experimen-
tal models and in humans. Possible risk factors were correlated to graft
histology. Donor age correlated strongly with mesangial matrix in-
crease, intimal proliferation, and tubular atrophy; there was no corre-
lation with interstitial changes. The number of acute rejections and cold
ischaemia time did not correlate with any one of the histological findings
at two years following transplantation. Cyclosporine dose and concen-
tration had a negative correlation to interstitial inflammation. A "chron-
ic allograft damage index" was eventually created for the comparison of
the four different treatment groups. The index consisted of those
tubular, glomerular, vascular and interstitial changes which correlated
best with decreasing graft function. The "chronic allograft damage
index" was significantly lower in the group that received triple therapy
than in the three other treatment groups with double-drug immunosup-
pressive therapy (Aza plus CsA, Aza plus MP, CsA plus MP). Our
results indicate that triple drug therapy is more efficacious than any of
the double drug regimens in the prevention of chronic changes. Fur-
thermore, our results demonstrate that even renal allografts with a good
and stable graft function demonstrate histopathological changes, though
mostly mild, which are in accordance with those seen in chronic
rejection.
Even after successful transplantation the lifetime of a renal
graft is generally restricted. The mean half life of a cadaveric
graft in the cyclosporine (CsA) era has been seven years [1].
This period has remained unchanged during the last two dec-
ades [2], and has not increased although one year graft survival
rates have increased.
The histological changes of renal allografts are usually inves-
tigated when the graft function has noticeably deteriorated [3,
4]. Almost all renal transplant biopsies obtained in the late
post-transplant period have shown histological features of
chronic rejection [5, 6]. To what extent do histological changes
occur in the grafts with a good function is not known. There is
limited evidence on the occurrence of histopathological
changes, which eventually may result in deteriorating graft
function, in stable and well-functioning transplants.
Both before and after transplantation the graft is shown to be
vulnerable to several factors such as preservation time, fre-
quency and intensity of acute rejections and the toxic effects of
therapeutic agents. Cyclosporine nephrotoxicity has been dem-
onstrated to cause fibrosis and tubular changes [3, 7—9] and
arteriolopathy [10—12], but none of these changes is specific to
CsA toxicity. Similar changes can be found in other disorders.
They were also seen in the renal allografts during the azathio-
prine era and they were commonly called "chronic" rejection
[13, 14].
Within a framework of a prospective randomized trial com-
paring various two and three drug immunosuppressive proto-
cols, the intensity and frequency of histological changes were
investigated using protocol biopsies in a large number of
consecutive, first cadaveric allografts at two years after trans-
plantation. All grafts were biopsied regardless of graft function
and evaluated blindly for all possible histological alterations;
the possible risk factors leading to allograft damage were also
evaluated. The histological changes which correlated to graft
function were used to calculate a "chronic renal allograft
damage index", which was then used to compare the effects of
different immunosuppressive regimens on histological graft
damage.
Nearly half of the patient population (46%) was on peritoneal
dialysis. All patients received at least three units of blood. HLA
matching was kept at a high level; 88% of the patient population
had no HLA antibodies before transplantation.
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Patients and clinical backgrounds
Between January 1986 and May 1987, 128 consecutive adult
patients in a single center with first cadaveric renal allograft
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recipients were included in a prospective, randomized trial
comparing triple-drug immunosuppressive treatment with low
dose CsA, Aza plus MP, to any combination of two immuno-
suppressive drugs [151. According to protocol all patients with
a functioning graft were biopsied two years post-transplanta-
tion. This prospective study includes 89 consecutive patients
with an adequate core biopsy of renal allografts two years after
successful transplantation.
The mean age of the patients was 44 years (SD 12 years),
mean age of donors 36 years (SD 14 years). All patients were on
dialysis before transplantation: 54% on hemodialysis and 46%
on peritoneal dialysis. Before transplantation all recipients
received at least three units of blood. HLA-matching was used
for patient selection. Mean HLA-AB incompatibility was 1.5
(SD 0.7) and HLA-DR incompatibility 0.9 (SD 0.7). Eighty-eight
percent of the patients had no panel reactive antibodies before
the transplantation. The mean cold ischemia time was 30 hours
(SD 7 hours). Twenty-one percent of the patients had diabetic
nephropathy.
Urological problems were very rare. There were no stricture
complications; only two patients had early leakage which were
successfully treated. Five patients have had arterial stenosis.
Four of five have been treated with percutaneous angioplasty
with good result and the fifth patient was unsuccessfully
treated. In the last case biopsy was contraindicated because of
high blood pressure. At two years 89% of patients were taking
at least one antihypertensive drug. The indications of these
drugs, that is whether the drug was used for hypertension or for
other reasons as coronary heart disease, were not analyzed in
this study. Blood pressure was recorded in every patient. Mean
of mean arterial pressure in all patients was 103 mm Hg.
Eighty-two of 89 patients were normotensive at the time of
biopsy.
In this study 20% of patients receiving triple therapy experi-
enced acute rejection during first 30 days post-transplantation
and 24% of patients experienced acute rejection before conver-
sion during 70 days post-transplantation. At ten weeks the
conversion after the initial triple therapy to double drug regimen
was associated with an increased risk of acute rejection when
MP (14% of patients) or cyA (36% of patients) was discontin-
ued, but all rejections were mild and reversible. Discontinua-
tion of Aza was not associated with rejections, and there were
no rejections in the group which continued with the triple
therapy. No grafts were lost due to acute rejection during the
two year follow-up in this study.
Two years after transplantation all patients with a functioning
graft were recalled for a check-up; 102 of 128 (80%) patients had
a functioning graft [161. On 13 occasions of the 102 patients, a
representative biopsy was not obtained: three patients refused
biopsy, four had biopsy contraindications (anticoagulant ther-
apy or hypertension), four biopsies were invalidated because of
technical problems while processing samples and two biopsies
were without glomeruli and were not included in this study.
At two years graft function tests, including serum creatinine,
serum urea, serum endogenous creatinine clearance, radionu-
clide I-13l-hippuran clearance and computer-generated serial
99m4echnetiumdiethylenetriaminepencetic acid (Tcm DTPA)
renal scan for perfusion index and mean transit time were
performed. For analysis the graft function of the patients was
divided into three categories according to serum creatinine
level; normal (C 115 itmol/Iiter), slightly increased (116 to 200
tsmol/liter) and increased (> 201 JLmol/liter). Ten of 13 patients
without biopsy had a normal serum creatinine, three others had
slightly increased and none had over 200 jzmol/liter.
Immunosuppression
The initial immunosuppression was triple therapy consisting
of low dose cyclosporine, low dose methylprednisolone (MP)
and azathioprine (Aza). The details of immunosuppression have
been reported earlier [15, 17]. Briefly, CsA was initiated at a
dose of 10 mg/kg per day and later adjusted to whole blood
trough levels for the entire treatment period. At ten weeks the
mean daily dose of CsA was 6.3 mg/kg, at one year 4.0 mg/kg
and at two years 3.2 mg/kg. Azathioprine was initiated at 2
mg/kg and decreased to 1 mg/kg on day 14 and later adjusted to
white blood cell count. At one year and at two years mean
actual dose of Aza was 1.4 mg/kg. Methylprednisolone was
administered at 1 mg/kg per day and tapered to 0.2 mg/kg per
day by day ten, and after one year the actual dose was 0.12
mg/kg; at two years the dose was 0.07 mg/kg per day.
At ten weeks the patients were randomized into four treat-
ment groups [15]. One group continued with triple therapy and
three other groups with any different combination of two drugs,
that is, Aza plus CsA, Aza plus MP, and CsA plus MP.
Biopsy technique and analysis
A percutaneous needle core biopsy was done with ultrasound
guidance and the use of an automated punch device (Biopty-
Cut, Radiplast, Bromma, Sweden). The transplant specimens
were obtained with a needle of 1.2 mm (outer diameter) which
yielded biopsies of 0.9 x 20 mm in size [18]. There were no
complications using this technique. All biopsies were fixed in
4% formaldehyde and embedded in paraffin. Serial 4 u thin
sections were stained using routine hematoxylin and eosin,
Masson' s trichrome, Unna-Pappenheim pyroninophilic stain,
periodic acid schiff (PAS) and methenamine silver PAS meth-
ods for light microscopic examination. The samples were coded
and examined by two independent observers who had no
knowledge of the clinical data of the patients. The mean number
of glomeruli was 7 per biopsy with a maximum of 20 glomeruli.
Histopathological changes were scored semiquantitatively from
0 to 3: 0 — none, 1 = mild, 2 = moderate, 3 = severe. In every
biopsy several different parameters were scored. The examined
morphological features of the interstitium, glomeruli, vessels,
and tubuli are listed in Table 1. The histopathological features
were classified as focal (less than 2 out of 4 visual fields) or
diffuse.
Statistical analysis
The differences in intensity of histological changes for more
than two groups were tested with Kruskall-Wallis non-paramet-
ric test, and for two groups with Mann-Whitney U-test. For
absolute numbers of the groups, chi-square test or Fishers's
exact tests were used. For testing the correlation between
histological findings and clinical parameters (serum creatinine
or CsA concentration), the Spearman rank correlation test was
used. The "chronic allograft damage index" was calculated
from the sum of diffuse inflammation and fibrosis in intersti-
tium, mesangial matrix increase and sclerosis of glomeruli,
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Table 1. Parameters evaluated in the histological specimens of
renal grafts
Interstitiuma Glomeruli
Inflammation Number of glomeruli
Lymphocytes Mesangial cell proliferation
Neutrophils Mesangial matrix increase
Macrophages Capillary basement membrane
Eosinophils thickening
Pyroninophilic cells Capillary basement membrane
Edema duplication
Hemorrhage Capillary thrombosis
Fibrin deposits Bowman capsular thickening
Fibrosis Glomerular inflammation
Glomerular sclerosis
Glomerular necrosis
Tubuli" Vesselsc
Epithelial swelling Endothelial swelling
Epithelial vacuolation isometric Endothelial proliferation
Epithelial vacuolation anisometric Intimal proliferation
Epithelial atrophy Inflammation
Necrosis Sclerosis
Casts Obliteration
Inflammation
Dilatation
Basement membrane thickening
Table 2. Renal function tests of 89 patients at two years
posttransplantation
Mean
Serum creatinine 148 mol/liter
Serum urea 9.8 mmol/liter
Serum endogenous creatinine clearance 56 mlIminIl.73 m2
Radionuclide I-'31-hippuran clearance 243 mllmin
Tc99mDTPA renal scan for perfusion index 122 %
Table 3. Incidence of most common histological findings occurring in
89 grafts
Interstitium
Diffuse inflammation
Diffuse lymphocytes
Diffuse pyronophilic cells
Diffuse fibrosis
Glomeruli
Mesangial matrix increase
Bowman capsular thickening
Glomerular sclerosis
Vessels
Intimal proliferation
Sclerosis
Tubuli
Epithelial swelling
Isometric vacuolation
Anisometric vacuolation
Tubular atrophy
BM thickening
Tubular dilatation
intimal proliferation of vessels and tubular atrophy. P values <
0.05 were considered significant.
Results
Clinical
The overall two year graft survival was 80% and patient
survival 87%. Graft and patient survivals in the four different
treatment groups were similar [16]. The mean serum creatinine
concentration at one year was 149 mot/liter (SD 72 tmol/liter)
and at two years 144 mol/liter (SD 62 molI1iter). There were
no significant differences in graft function among the four
treatment groups. There were no discrepancy between the
results of serum creatinine level and other more specific renal
function tests of allografts. Mean values of other renal function
tests of 89 grafts are presented in Table 2.
Of 89 patients with an adequate biopsy specimen, 37 patients
had normal creatinine (<115 /Lmol/liter), 32 patients had slightly
increased creatinine (116 to 200 mo1Iliter) and 20 patients had
increased creatinine (>201 mol11iter).
Most common histopathological findings
Table I presents the histological parameters evaluated. Table
3 shows the most common histological findings in the allografts.
The changes were scored usually mild, severe changes were
seldom found.
Interstitium. Diffuse fibrosis was present in 2/3 biopsies,
changes were scored mild in 36% of biopsies, moderate in 20%
of biopsies and severe in 6%. In biopsies with severe changes,
all patients except one received CsA plus MP as immunosup-
pressive therapy. Focal fibrosis was present in 33% of the
biopsies and was scored mostly mild or moderate.
Glomeruli. There were three main changes. A mild mesangial
increase was present in 37% of the grafts and only 2% had
severe changes. Bowman capsular thickening and glomerular
sclerosis was scored mild in 2/3 of the grafts; only a few grafts
(3%) had severe glomerular sclerosis.
Vessels. The most often seen pathological feature (36%) was
intimal proliferation in graft vessels. Sclerosis of the vessels
was scored mild in 21% of biopsies, moderate in 6% and severe
in 0%.
Tubli. Half of the grafts displayed a mild anisometric tubular
vacuolation. Isometric vacuolation was less frequent (12%). All
patients with isometric vacuolation, except two, received cy-
closporine at the time of the biopsy. One of these two patients
had discontinued to take cyclosporine four months prior to
biopsy, and the other one month before. Atrophy was the most
often seen tubular abnormality (64%). It was moderate in 22%
and severe in 2% of the biopsies. Basement membrane thick-
ening and tubular dilatation and epithelial swelling were also
occasionally encountered.
Correlation of histopathological findings to graft function
Interstitial inflammation and fibrosis increased together with
deteriorating graft function (Table 4). The same tendency was
seen in glomerulosclerosis and mesangial matrix increase. Inti-
mal proliferation tended to intensify with increasing serum
All specimens were coded and histopathological changes were scored
semiquantitatively from 0—3; 0 = none, I = mild, 2 = moderate and 3 =
severe. Separately for a diffuse and focal changes; b proximal and distal
tubules; arteries, arterioles and veins.
30%
24%
18%
62%
37%
26%
43%
36%
27%
36%
12%
50%
64%
25%
15%
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Creatinine
Slightly
Normal
< 115
mol/liter
increased
116—200
mol/1iter
Increased
<200
smol/1iter P
Number of patients with 37 32 20
biopsy
Mean number of 7.2 7.8 7.3 NS
glomeruli
Interstitium
Diffuse inflammation 0.2 0.1 0.4 0.1 0.7 0.2 0.0435
Diffuse lymphocytes 0.1 0.1 0.3 0.1 0.6 0.2 NS
Diffuse pyronophilic 0.1 0.1 0.2 0.1 0.4 0.2 NS
cells
Diffuse fibrosis 0.4 0.1 0.7 0.2 1.5 0.2 0.0002
Glomeruli
Mesangial matrix 0.1 0.0 0.5 0.1 0.7 0.1 0,006
increase
Bowman capsular 0.2 0.1 0.3 0.1 0.3 0.2 NS
thickening
Gloinerular sclerosis 0.2 0.1 0.8 0.2 0.7 0.2 0.043
Vessels
Intimal proliferation 0.2 0.1 0.4 0.1 0.6 0.2 NS
Sclerosis 0.2 0.1 0.4 0.1 0.4 0.1 NS
Tubuli
Epithelial swelling 0.3 0.1 0.4 0.1 0.3 0.1 NS
Isometric vacuolation 0.1 0.0 0.2 0.1 0.1 0.1 NS
Anisometrjc 0.4 0.1 0.3 0.1 0,4 0.1 NS
vacuolation
Tubular atrophy 0.4 0.1 0.8 0.1 1.3 0.2 0.0001
BM thickening 0.2 0.1 0.2 0.1 0.5 0.2 NS
Tubular dilatation 0.0±0.0 0.2 0.1 0.4 0.2 NS
creatinine, but the differences were without statistical signifi-
cance. Tubular atrophy was more more prominent with poor
graft function.
Correlations to clinical parameters
The effects of the age of the donors on the histological
findings analyzed by dividing the patients into two groups: one
group of patients was selected with donor age under 40 years
and the other over 40 years. There were significantly more
findings in glomeruli, vessels and tubuli in the group with older
donors, but not in the interstitium (Table 5). Serum creatinine
was significantly lower in the group of patients with a younger
donor. In the three groups based on the serum creatinine
values, that is, normal, slightly increased and increased, the
mean age of donor was 28 years (SD 12 years), 38 years (SD 13
years) and 42 years (SD 14 years), respectively (P = 0.0004).
Interstitial changes, especially fibrosis, correlated strongly
with graft function but not with donor age (Table 6). Both the
graft function and the age of donor correlated with tubular,
vascular and glomerular changes.
Cyclosporine effect was tested as to concentration and dose
(Table 6). Inflammation with pyronophilic cells was correlated
both with dose and concentration in a negative fashion: the
higher the dose, the less active inflammation was present. The
other change which correlated with CsA was a basement
membrane thickening in tubuli.
Table 5. Serum creatinine and significant differences in histological
findings of grafts according to donors age
Number of patients
Creatinine
Interstitium: no significant
differences
Glomeruli
Mesangial matrix
increase
Glomerular sclerosis
Vessels
Intimal proliferation
Tubuli
Tubular atrophy
Data are presented as mean SE.
Mann-Whitney
U test
P
age of donor
Serum Age of Cyclosporine Cyclosporine
Histological finding
creatinine donor dose concentration
P
Interstitium, diffuse
Diffuse 0.005 NS o.osa o.o3a
inflammation
Diffuse 0.007 NS NS NS
lymphocytes
Diffuse 0.041 NS 0.05a 0.0l
pyronophilic
cells
Diffuse fibrosis 0.0002 NS NS NS
Glomeruli
Mesangial matrix 0.0015 0.0046 NS NS
increase
Bowman capsular NS NS NS NS
thickening
Glomerular 0.0019 0.0184 NS NS
sclerosis
Vessels
Intimal 0.0483 0.0013 NS NS
proliferation
Sclerosis NS NS NS NS
Tubuli
Epithelial NS NS NS NS
swelling
Isometric NS NS NS NS
vacuolation
Anisometric NS NS NS NS
vacuolation
Tubular atrophy 0.0001 0.0001 NS NS
BM thickening NS NS 0.02 NS
Tubular dilatation 0.0065 NS NS NS
In this study we did not find any correlation between the cold
ischaemia time and histopathological changes in any one of the
measured variables.
For testing the effect of acute rejection episodes, the findings
in the grafts were divided into two groups: patients which had
an acute rejection during the first six months and patients which
had not. There were no differences in histological features
Table 4. Intensity of histopathological findings according to graft
function
Donor age Donor age
<40 years >40 years
60 29
128±7 190±11
0.25 0.06 0.64 0.14
0,33 0.07 0.90 0.17
0.24 0.06 0.66 0.12
0.44 0.08 1.3 0.11
0.0001
0.014
0.002
0.001
0.0001
Table 6. Correlation of histological findings to serum creatinine and
Data are presented as mean s.
a Kruskall-Wallis test used
Spearman rank correlation coefficient used for statistics.
a Negative correlation
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Table 7. Chronic allograft damage index in different treatment groups
Treatment group
Aza+ Aza+ CsA+
Triple CsA MP MP Kruskall-
19 23 25 22 Wallis
Interstitum
Diffuse inflammation 0.2 0.4 0.4 0.3
Fibrosis 0.4 0.7 0.8 1.2
Glomeruli
Mesangial matrix 0.1 0.5 0.3 0.6
increase
Sclerosis of glomeruli 0.2 0.6 0.6 0.6
Vessels
Intimal proliferation 0.3 0.3 0.2 0.7
Tubuli
Tubular atrophy 0.3 0.7 0.9 0.9
Chronic allograft damage 1.5 3.2 3.2 4.3 0.009
indexa
Index is formed of those histopathological changes which correlated
to decreasing graft. Kruskall-Wallis nonparametric test used for statis-
tics.
Sum of mean scores per patient per group
between these two groups, neither in the intensity nor in the
frequency of histological changes.
Biopsies of the patients with type I diabetes were analyzed
separately. There were no statistical differences in the intensity
or frequency in any variables (including glomerular and vascu-
lar changes) between diabetic and other patients. Two patients
had recurrence of original glomerulonephritis.
We did not study the degree of hypertension as a contributing
factor in morphologic and functional changes in the kidneys of
these transplant patients.
The histological "chronic allo graft damage index" for
comparison of four dj/ferent treatment regimens
A "chronic allograft damage index" was created for com-
parison of the four different treatment groups. The index
consisted of those histological changes which correlated in our
study with decreasing graft function, and which changes have
previously been associated in the literature to chronic rejection
and CsA toxicity. The index was calculated as the sum of
scores: a) of diffuse inflammation and fibrosis in interstitium, b)
of mesangial matrix increase and sclerosis of glomeruli, c) of
intimal proliferation of vessels and d) of tubular atrophy.
The "chronic allograft damage index" was lowest in the
triple therapy group (1.5) compared with other treatment groups
with two immunosuppressive drug regimens (3.2 for Aza plus
CsA; 3.2 for Aza plus MP and 4.3 for CsA plus MP). The
difference to the triple therapy group was significant (P = .009;
Table 7). The most significant differences between the four
treatment groups were mesangial matrix increase of glomeruli
(P 0.01) and vascular sclerosis (P = 0.03), both being less
frequent in the triple therapy group.
Discussion
This prospective study is an evaluation of the histological
findings in 89 first cadaveric renal allografts two years after
transplantation. Most of the patients had normal or only slightly
increased serum creatinine level at the time of biopsy. However
the histological analyses showed that 2/3 of the grafts had
fibrosis and tubular atrophy, and more than 1/3 of the grafts had
glomerular sclerosis and intimal proliferation in the vessels. In
most cases the changes were scored mild.
All these histological changes have been described previously
in connection with chronic rejection [19], which is clinically
defined as a gradual but progressive decline in graft function.
Regardless, that the one year GS rates have improved signif-
icantly with CsA, the long term results of the half-life of a
kidney graft have remained very much the same [2]. The
clarification of the possible risk factors which are responsible
for these changes are becoming more important. Several of
these risk factors were analyzed in this study.
In our study graft function correlated strongly with donor
age, although the mean age of donors was only 35 years. There
was a signiñcant difference in donor age between the groups
with normal graft function and with slightly decreased graft
function at two years. When investigating the histological
features, donor age correlated strongly with glomerular, vascu-
lar and tubular changes, but not with interstitial changes. This
observation confirms that graft survival is less adequate when
very old or very young donors are employed [20, 21] and
extends these findings also to middle age groups.
Our findings do not support the theory that the initial damage
of allograft, due to long cold ischemia time or acute rejections,
leads to chronic damage of allograft. In this study none of the
histological findings did correlate to these parameters. In our
study the histological changes seen at two years cannot be
explained by earlier acute rejection. One explanation for this
might be that triple drug therapy was used during the time when
the risk of acute rejection is highest, and with triple therapy the
rejections were not only seldom seen but they also were milder
than in earlier studies with correlation of graft histology to
rejections. No grafts were lost due to acute rejection during the
two year follow-up. However, we must remember that only first
transplants were included.
Hypertension might have some effects on histology of renal
allografts. Even hypertensive drugs, for example, angiotensin
converting enzyme inhibitors and calcium antagonists, have
been reported to have some inhibitory effects on arteriosclero-
sis. Only two patients received angiotensin converting enzyme
inhibitors, but calcium antagonists were very common. How-
ever, at the time of biopsy 92% of patients were normotensive
with treatment. We did not stratify the degree of severity of
hypertension according to the number of medications used to
control it.
Many studies employing a high initial CsA dose have shown
significantly more fibrosis in the grafts with CsA than those
without [3, 7]. In randomized studies with an early conversion
from CsA to Aza, there have been no histological differences in
the CsA to Aza conversion group compared with the group
maintained on Aza plus steroids only [22]. A randomized study
comparing triple therapy with CsA plus steroid, showed more
fibrosis with double therapy than with triple therapy [231. In our
study there was less fibrosis with triple therapy than with any of
the double drug regimens, including the Aza plus MP regimen.
The fibrosis in the Aza plus MP group was approximately
similar as in the groups receiving CsA plus MP or CsA plus
Aza. The fibrosis may thus be the result of either CsA nephro-
toxicity, or chronic rejection, or both. We are interpreting our
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results that triple therapy resulted in a better control in prevent-
ing chronic rejection than any one of the double drug regimens,
and resulted, therefore, in less prominent changes in the graft.
This suggestion is substantiated by an earlier finding in this
study that there is significantly less interstitial inflammation in
grafts of the triple therapy group compared to any one of the
double therapy group (unpublished observations). Cyclosporine
may have some effect in causing fibrosis in the triple therapy
group as well, but this is less evident possibly as low doses were
used initially.
In the CsA era the main questions have been the nephrotox-
icity of cyclosporine and the differential diagnosis between
nephrotoxicity and acute rejection [4, 24]. There is evidence
that cyclosporine, when used initially in low doses [23, 25] or
after an initial use with conversion to Aza [221, does not cause
more fibrosis than do other modes of treatment. In this study
cyclosporine was used in low doses during the entire treatment
period and according to blood concentrations. We found a
negative correlation of cyclosporine dose or concentration only
to inflammation, but not with fibrosis or glomerular or vascular
change as described earlier, when the drug was used with higher
doses. There was no significant correlation of CsA dose or
concentration with isometric vacuolation either, though all
patients with isometric vacuolation in proximal tubules of the
graft had CsA in their treatment.
The Aza plus MP group showed as severe histological
changes as the CsA plus MP group. The best group with least
histological changes in every respect, was the triple therapy
group, which we interpret of being due to the result of better
immunosuppression which prevents chronic changes. The
"chronic allograft damage index," which was calculated using
the parameters correlating to graft function, was significantly
lower in the triple therapy group when compared to the others.
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